OpenAI Misses Targets, Codex vs Claude, Elon vs Sam Trial, Big Hyperscaler Beats, Peptide Craze

The AI industry faces significant supply-side constraints as hyperscalers like Amazon, Microsoft, Google, and Meta commit over $700 billion in capital expenditure to secure the power and compute necessary for token generation. While OpenAI missed consumer growth and revenue targets, enterprise demand for coding and security applications remains robust, driving a shift toward specialized small language models and efficient inference techniques. Simultaneously, the legal battle between Elon Musk and OpenAI over charitable trust obligations highlights growing tensions regarding the transition from non-profit research to for-profit commercialization. Beyond AI, the emergence of advanced GLP-1 and glucagon receptor agonists, such as Retatrutide, promises transformative health outcomes for obesity and metabolic disease, while the Supreme Court’s deliberative process serves as a benchmark for institutional stability amidst broader economic and technological shifts.